Treatment with tregs safe, may slow ALS progression: Trial

Treatment with tregs safe, may slow ALS progression: Trial

Treatment with regulatory T-cells, or Tregs — a type of anti-inflammatory immune cell — was well tolerated and seemed to slow disease progression in a small clinical trial that enrolled six people with amyotrophic lateral sclerosis (ALS). The work was conducted by scientists at Columbia University in New York, in collaboration with Cellenkos, a clinical-stage biotechnology company that’s developing a modified Treg therapy called CK0803 as a trea…